Adalimumab (Hyrimoz, Amjevita)

Biosimilars approved for adalimumab

After most drug's patent expires the formula becomes public domain and generic drugs can be made by companies willing to invest in them. The formula of complicated and expensive drugs called biologic drugs for autoimmune disease are not released to the public, but after patent expires, a company can produce a biosimilar version if their scientists can devise the formula on their own.  Humira, brand name of adalimumab, is one of the most financially and medically successful drugs ever made. Now, after 24 years, biosimilar versions are being released. Amjevita was the first announced and now Hyrimoz, produced by Sandoz pharmaceuticals, will be available in July 2023.  [1]